Veracyte, Inc. company information, Employees & Contact Information

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 Business Wire

36% Higher Survival Rate: Groundbreaking Veracyte Test Revolutionizes Prostate Cancer Treatment Selection Stock Titan

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer The AI Journal

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Business Wire

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 Business Wire

Veracyte at Morgan Stanley Conference: Strategic Growth and Innovation Investing.com

Veracyte Announces Second Quarter 2025 Financial Results Business Wire

Veracyte to Participate in Upcoming Investor Conferences FinancialContent

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle Stock Titan

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting Business Wire

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors Stock Titan

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test Business Wire

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 Business Wire

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 Business Wire

Veracyte Announces First Quarter 2025 Financial Results Business Wire

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results Business Wire

Decipher test is predictive of chemotherapy benefit in metastatic prostate cancer Urology Times

Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision Business Wire

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference The AI Journal

Veracyte Appoints Annie McGuire as General Counsel Business Wire

Veracyte, Inc. Announces CEO Succession Plan Business Wire

Veracyte at William Blair Growth Stock Conference: Strategic Insights Unveiled Investing.com

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year citybiz

Decipher prostate test receives high evidence rating in NCCN guidelines Urology Times

Prostate cancer genomic tests show prognostic value for progression, therapy benefit Urology Times

VCYT - Veracyte Latest Stock News & Market Updates Stock Titan

Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary Business Wire

Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations Frontiers

Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Through Agreement with Quest Diagnostics PR Newswire

Veracyte Appoints Keith Kennedy as Chief Financial Officer PR Newswire

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year FinancialContent

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022 FinancialContent

Veracyte to Present at Upcoming Investor Conferences FinancialContent

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022 FinancialContent

Pittsburgh Post-Gazette FinancialContent

Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data The Lancet

Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology The New England Journal of Medicine

National Survey Reveals Patients with Potentially Deadly Interstitial Lung Diseases are Enduring Significant Diagnosis Delays and Errors MultiVu